Autopsy report · NCT05304130

A Study in Healthy Japanese Participants to Evaluate the Safety and Pharmacokinetics of Otilimab

“This study was cancelled because of the limited efficacy demonstrated in the ContRAst phase III programme as a potential treatment for rheumatoid arthritis. GSK has decided not to progress with regulatory submissions”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

GlaxoSmithKline

Sponsor type

Industry

Conditions

Arthritis, Rheumatoid

Interventions

Otilimab

Participants

0

Trials that died the same way

• Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
  “The clinical development of intravenously administered ofatumumab in RA will no longer be pursued, so this study was prematurely terminated by the Sponsor.” (59% match in meaning)
• Safety and Efficacy of AMG 827 in Subjects With RA
  “Lack of efficacy for Brodalumab in Rheumatoid Arthritis (RA)” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.